Prosecution Insights
Last updated: November 08, 2026
Application No. 18/840,429

SOLID FORMS OF ALECTINIB AND ALECTINIB SALTS

Non-Final OA §102§103
Filed
Aug 21, 2024
Priority
Feb 22, 2022 — EU 22157941.0 +3 more
Examiner
PATEL, SAGAR S
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Synthon B.V.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
362 granted / 479 resolved
+15.6% vs TC avg
Strong +35% interview lift
Without
With
+35.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
28 currently pending
Career history
506
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
38.0%
-2.0% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 479 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 16 – 31 are pending. Claims 16 – 18 and 20 – 31 are rejected. Claim 19 is objected. Priority PNG media_image1.png 126 388 media_image1.png Greyscale Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on August 21, 2024 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Objections Claim 19 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 16 and 30 – 31 are rejected under 35 U.S.C. 102(a)(1)/102(a)(2) as being anticipated by Furumoto et al. US2013/0143877 A1. Furumoto et al. teach compound F6-20 (Alectinib) of Production Example 30: PNG media_image2.png 232 472 media_image2.png Greyscale . See, e.g., paragraph [0678]. Furumoto further teaches mesylate salt (methane sulfonate salt) of compound F6-20 is prepared by dissolving compound F6-20 in dimethyl acetamide at 90 °C, adding aqueous solution of mesylic acid, filtering and drying the precipitated crystals, and pulverizing the monomesylate salt using a jet mill (solid form in claim 31). See, e.g., paragraph [0686]. Therefore, the prior art anticipates the instant claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 16 – 18 and 20 – 31 are rejected under 35 U.S.C. 103 as being unpatentable over Furumoto et al. US2013/0143877 A1 in view of Berge et al., Journal of Pharmaceutical Sciences (1977), 66(1), pp. 1-19 (pub. January 1, 1977). Determining the scope and contents of the prior art Furumoto et al. teach compound F6-20 (Alectinib) of Production Example 30: PNG media_image2.png 232 472 media_image2.png Greyscale . See, e.g., paragraph [0678]. Furumoto et al. does not teach the acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20. Berge et al. teach that “[t]he chemical, biological, physical, and economic characteristics of medicinal agents can be manipulated and, hence, often optimized by conversion to a salt form”. See, e.g., pg. 1, 1st paragraph. Berge et al. teach that acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts are common FDA-approved commercially marketed salts known to be useful for formulation of salts of drugs. See, e.g., pg. 2, Table I. PNG media_image3.png 69 352 media_image3.png Greyscale PNG media_image4.png 18 323 media_image4.png Greyscale PNG media_image5.png 19 332 media_image5.png Greyscale PNG media_image6.png 36 353 media_image6.png Greyscale Berge also teaches that combining a known drug with one of the anions or cations to prepare the salt does not affect the basic therapeutic properties of the drug, but is used to “prolong the release of the active component, thereby eliminating various undesirable drug properties”. See, e.g., pg. 1, 4th paragraph. Ascertaining the differences between the prior art and the claims at issue Compared to claims 16 – 18 and 20 – 31, Furumoto et al. does not specifically teach the acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20. Rationale for a prima face case of obviousness According to MPEP §2141(III), one of the rationales in the KSR decision states “(C) Use of known technique to improve similar devices (methods, or products) in the same way”. KSR, 550 U.S. at 418, 82 USPQ2d at 1396. Furumoto teaches mesylate salt (methane sulfonate salt) of compound F6-20 is prepared by dissolving compound F6-20 in dimethyl acetamide at 90 °C, adding aqueous solution of mesylic acid, filtering and drying the precipitated crystals, and pulverizing the monomesylate salt using a jet mill (solid form). See, e.g., paragraph [0686]. Berge et al. teach that acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts are few of the most common FDA-approved commercially marketed salts known to be useful for formulation of salts of drugs. See, e.g., pg. 2, Table I. PNG media_image3.png 69 352 media_image3.png Greyscale PNG media_image4.png 18 323 media_image4.png Greyscale PNG media_image5.png 19 332 media_image5.png Greyscale PNG media_image6.png 36 353 media_image6.png Greyscale Berge et al. also teaches that preparing an anion salt of the known drug does not affect the therapeutic properties of the drug, but rather prolongs the release of the drug and eliminates various undesirable drug properties. Thus, using the teachings of Berge to obtain the solid forms of acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts of compound F6-20 would be the same as using a known technique in the art for preparing pharmaceutically acceptable salts to improve similar compounds in the same way. Therefore, the PHOSITA would have been motivated to prepare the solid forms of said salts of acetate, tartaric acid, maleic acid, fumaric acid (1:1), fumaric acid (1:2) and ethane sulfonate (esylate) salts in a similar method of preparing the mesylate salt of compound F6-20 as taught by Furumoto et al. in order to improve the pharmaceutical properties of alectinib. Therefore, the prior art render the instant claims prima facie obvious. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sagar Patel whose telephone number is (571)272-1317. The examiner can normally be reached Monday - Friday: 9am to 5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Sagar Patel/Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Aug 21, 2024
Application Filed
Sep 22, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780816
SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF
2y 3m to grant Granted Nov 03, 2026
Patent 12751953
MRGX Receptor Antagonists
6y 11m to grant Granted Oct 06, 2026
Patent 12740950
SHORT CONJUGATED OLIGOELECTROLYTESAND ANTIBIOTICS
4y 4m to grant Granted Sep 22, 2026
Patent 12741933
SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS
3y 5m to grant Granted Sep 22, 2026
Patent 12729169
DIRECT AROMATIC CARBON-OXYGEN AND CARBON-HYDROGEN BOND FUNCTIONALIZATION VIA ORGANIC PHOTOREDOX CATALYST
5y 0m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+35.2%)
2y 6m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 479 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month